SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2775)2/9/2011 6:52:29 PM
From: tuck  Read Replies (1) | Respond to of 3661
 
I toyed with getting out for a modest gain recently. Sorry I did not now. They appear to have fallen behind in the race to be part of the future HepC SOC, oral combos of nukes & PIs.

Will probably look for a bounce back to $4 and get out. Unless they pull something off that looks like it has staying power.

They are late on starting their proof of concept trial for 375, aren't they? A three day trial, maybe results will give it a little pop. Could be done this year if they don't drag their feet too long.

But not sure what the commercial road map is without 320.

Cheers, Tuck



To: DewDiligence_on_SI who wrote (2775)6/20/2013 5:06:14 PM
From: tuck  Read Replies (1) | Respond to of 3661
 
Idenix (IDIX) off 27% for the day, as the FDA puts clinical hold on a their lead uridine nucleotide prodrug, which was heading for P1.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News